People with a rare form of cancer which occurs in the muscles, nerves, fat or blood vessels could benefit from a new treatment, it was announced today.
The National Institute for Health and Clinical Excellence (Nice) has reversed an earlier decision on the drug trabectedin after the manufacturers agreed to a cost-reducing scheme.
Under the plan, the firm PharmaMar will meet the cost of the drug if it is needed beyond a fifth cycle of treatment.
The medicine could extend the lives of people with advanced soft tissue sarcoma by at least three months.
Trabectedin will benefit around 110 patients a year who have failed on other treatments, at a cost of more than £3,500 a cycle.
The drug, which is given intravenously, works by altering the DNA in cancer cells, which stops them growing and spreading.